Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 02  STN pricing information for 2008 now available
 NEWS  3  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS  4  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS  5  JAN 28  MARPAT searching enhanced
 NEWS  6  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS  7  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08  STN Express, Version 8.3, now available
 NEWS 10  FEB 20  PCI now available as a replacement to DPCI
 NEWS 11  FEB 25  IFIREF reloaded with enhancements
 NEWS 12  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification
 NEWS 14  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS 15  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS 16  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS 17  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04  STN AnaVist, Version 1, to be discontinued
 NEWS 20  APR 15  WPIDS, WPINDEX, and WPIX enhanced with new
                  predefined hit display formats
 NEWS 21  APR 28  EMBASE Controlled Term thesaurus enhanced
 NEWS 22  APR 28  IMSRESEARCH reloaded with enhancements
 NEWS 23  MAY 30  INPAFAMDB now available on STN for patent family
                  searching
 NEWS 24  MAY 30  DGENE, PCTGEN, and USGENE enhanced with new homology
                  sequence search option
 NEWS 25  JUN 06  EPFULL enhanced with 260,000 English abstracts
 NEWS 26  JUN 06  KOREAPAT updated with 41,000 documents
 NEWS 27  JUN 13  USPATFULL and USPAT2 updated with 11-character
                  patent numbers for U.S. applications
 NEWS 28  JUN 19  CAS REGISTRY includes selected substances from
                  web-based collections
 NEWS 29  JUN 25  CA/CAplus and USPAT databases updated with IPC
                  reclassification data
 NEWS 30  JUN 30  AEROSPACE enhanced with more than 1 million U.S.
                  patent records
 NEWS 31  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

McIntosh

```
Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:53:44 ON 28 JUL 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 08:54:03 ON 28 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 JUL 2008  HIGHEST RN 1036536-16-9
DICTIONARY FILE UPDATES:  27 JUL 2008  HIGHEST RN 1036536-16-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10540993d.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 08:54:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      447 TO ITERATE

100.0% PROCESSED      447 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         7672 TO    10208
PROJECTED ANSWERS:            1692 TO     2988

L2           50 SEA SSS SAM L1
```

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Adenosine, 2-amino-N-[(4-chloro-3-nitrophenyl)methyl]- (9CI)
MF C17 H18 Cl N7 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Adenosine, 2-bromo-N-[(4-hydroxy-2,6-dimethoxyphenyl)methyl]- (9CI)
MF C19 H22 Br N5 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Adenosine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-2-fluoro- (9CI)
MF C21 H26 F N5 O4

Absolute stereochemistry.

McIntosh



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Adenosine, 2-amino-N-[(2,6-dihydroxy-3-methoxyphenyl)methyl]- (9CI)
MF C18 H22 N6 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Adenosine, N-[(2-amino-5-chlorophenyl)methyl]-1,2-dihydro-2-oxo- (9CI)
MF C17 H19 Cl N6 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Adenosine, N-[(5-fluoro-2-hydroxyphenyl)methyl]-2-methyl- (9CI)
MF C18 H20 F N5 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.76	2.97

FILE 'CAPLUS' ENTERED AT 08:57:27 ON 28 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Jul 2008 VOL 149 ISS 5
FILE LAST UPDATED: 27 Jul 2008 (20080727/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d scan
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d his

     (FILE 'HOME' ENTERED AT 08:53:44 ON 28 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 08:54:03 ON 28 JUL 2008
L1   STRUCTURE UPLOADED
L2   50 S L1

     FILE 'CAPLUS' ENTERED AT 08:57:27 ON 28 JUL 2008

=> s l2
L3   5 L2

=> d bib abs

L3   ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN   2007:474159 CAPLUS
DN   147:143613
TI   Preparation, biological activity and endogenous occurrence of
     N6-benzyladenosines
AU   Dolezal, Karel; Popa, Igor; Hauserova, Eva; Spichal, Lukas; Chakrabarty,
     Kuheli; Novak, Ondrej; Krystof, Vladimir; Voller, Jiri; Holub, Jan;
     Strnad, Miroslav
CS   Laboratory of Growth Regulators, Palacky University & Institute of
     Experimental Botany AS CR, Olomouc, 783 71, Czech Rep.
SO   Bioorganic & Medicinal Chemistry (2007), 15(11), 3737-3747
     CODEN: BMECEP; ISSN: 0968-0896
PB   Elsevier Ltd.
DT   Journal
LA   English
OS   CASREACT 147:143613
GI



I

AB   Cytokinin activity of forty-eight 6-benzyladenosine derivs., e.g. I, at
     both the receptor and cellular levels as well as their anticancer

properties were compared in various in vitro assays. The compds. were prepared by the condensation of 6-chloropurine riboside with corresponding substituted benzylamines and characterized by standard collection of physico-chemical methods. The majority of synthesized derivs. exhibited high activity in all three of the cytokinin bioassays used (tobacco callus, wheat leaf senescence and Amaranthus bioassay). The highest activities were observed in the senescence bioassay. For several of the compds. tested, significant differences in activity were found between the bioassays used, indicating that diverse recognition systems may operate. This suggests that it may be possible to modulate particular cytokinin-dependent processes with specific compds. In contrast to their high activity in bioassays, the tested compds. were recognized with only very low sensitivity in both Arabidopsis thaliana AHK3 and AHK4 receptor assays. The prepared derivs. were also investigated for their antiproliferative properties on cancer and normal cell lines. Several of them showed very strong cytotoxic activity against various cancer cell lines. On the other hand, they were not cytotoxic for normal murine fibroblast (NIH/3T3) cell line. This anticancer activity of cytokinin ribosides may be important, given that several of them occur as endogenous compds. in different organisms.

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs 2-5

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:796168 CAPLUS
DN 145:230849
TI Preparation of nucleoside derivatives as inhibitors of E1 activating enzymes
IN Critchley, Stephen; Gant, Thomas G.; Langston, Steven P.; Olhava, Edward J.; Peluso, Stephane
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 214pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006084281	A1	20060810	WO 2006-US4637	20060202
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006210422	A1	20060810	AU 2006-210422	20060202
	CA 2596424	A1	20060810	CA 2006-2596424	20060202
	US 20060189636	A1	20060824	US 2006-346469	20060202
	EP 1848718	A1	20071031	EP 2006-734691	20060202
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	IN 2007DN06144	A	20070831	IN 2007-DN6144	20070807
PRAI	US 2005-650433P	P	20050204		
	WO 2006-US4637	W	20060202		

OS MARPAT 145:230849
GI



I

AB Nucleoside derivs. I, wherein A is substituted purine derivs.; X is CH2, CHF, CF2, NH, O; Y is O, S, substituted carbon; each R is independently H, F, aliphatic, fluoro-aliphatic; two R, taken together with the carbon atom to which they are attached, form a 3- to 6-membered carbocyclic ring; or one R, taken together with R1 and the intervening carbon atoms, forms a 3- to 6-membered spiro-cyclic ring; or two R together form O; R1 is H, or aliphatic; R and R1 taken together with the intervening carbon atoms form a 3- to 6-membered spiro-cyclic ring; R2 and R5 are independently is H , F , CN, N3, OH , alkoxy, substituted hydrazine, carbamate, amide, acyl, oxy-amide, ester, oxy-carboxylate, fluoro-aliphatic, aliphatic; R3 is H , F , aliphatic, fluoro-aliphatic; R4 is H, F, aliphatic, fluoro-aliphatic; R6 is H, aliphatic; n is 1-3; were prepared as inhibitors of E1 activating enzymes and useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. Thus, [(2R,3S,4R,5R)-5-[6-((1S)-2,3-dihydro-1H-inden-1-ylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]methyl sulfamate was prepared and tested in vitro and in mice as inhibitor of E1 activating enzyme. The compds. are designed to be inhibitors of Nedd8-activating enzyme (APPBP1-Uba3) (NAE), ubiquitin activating enzyme (UAE), and/or activating enzyme (Aos1-Uba2) (SAE).
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:634314 CAPLUS
DN 141:296236
TI 2-Pyrazolyl-N6-Substituted Adenosine Derivatives as High Affinity and Selective Adenosine A3 Receptor Agonists
AU Elzein, Elfatih; Palle, Venkata; Wu, Yuzhi; Maa, Tenning; Zeng, Dewan; Zablocki, Jeff
CS Department of Bioorganic Chemistry and Department of Drug Research and Pharmacological Sciences, CV Therapeutics Inc., Palo Alto, CA, 94304, USA
SO Journal of Medicinal Chemistry (2004), 47(19), 4766-4773
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:296236
AB The authors describe the synthesis of new high affinity and selective A3-adenosine receptor (A3-AdoR) agonists. Introduction of a Me group at the N6-position of the A2A-AdoR selective 2-pyrazolyl-adenosine analogs (Figure 2) brought about a substantial increase in the A3-AdoR binding affinity and selectivity. While the N6-desmethyl analogs were inactive at the A3-AdoR (Ki > 10 μM), the corresponding N6-Me analogs showed good binding affinity at the A3-AdoR (Ki = 73 and 97 nM, resp.). Replacement of the carboxamide group with different heteroaryl groups resulted in analogs with high affinities and selectivity for the A3-AdoR. (2R,3S,4R)-Tetrahydro-2-(hydroxymethyl)-5-(6-(methylamino)-2-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)-9H-purin-9-yl)furan-3,4-diol (Ki = 2 nM) displayed high selectivity for the A3-AdoR vs. A1- and A2A-AdoRs (selectivity ratios of 1900 and >2000, resp.).
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:566634 CAPLUS
DN 141:123865
TI Substitution derivatives of N6-benzyl-adenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
IN Dolezal, Karel; Popa, Igor; Zatloukal, Marek; Lenobel, Rene; Hradecka, Dana; Vojtesek, Borivoj; Uldrijan, Stjepan; Mlejnek, Petr; Werbrouck,

Stefaan; Strnad, Miroslav
PA Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky, Czech Rep.; et al.
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058791	A2	20040715	WO 2003-CZ78	20031229
	WO 2004058791	A3	20041028		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CZ 294538	B6	20050112	CZ 2002-4273	20021230
	AU 2003294608	A1	20040722	AU 2003-294608	20031229
	EP 1575973	A2	20050921	EP 2003-785482	20031229
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	ZA 2005006074	A	20060531	ZA 2005-6074	20050728
	US 20060166925	A1	20060727	US 2005-540993	20050815
PRAI	CZ 2002-4273	A	20021230		
	WO 2003-CZ78	W	20031229		

OS MARPAT 141:123865
GI



I

AB The invention concerns novel substitution derivs. of N6-benzyl-adenosine I, wherein n is 2-6; R1 is H, OH, halogen, alkoxy, amino, hydrazo, mercapto, methylmercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, carbylalkoxy, cycloalkyl, carbamoyl alkyl; R2 is H, OH, halogen, alkoxy, amino, hydrazo, mercapto, methylmercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, cabylalkoxy, cycloalkyl, carbamoyl, having anticancer, mitotic, immunosuppressive and anti-senescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyl-adenosine derivs. and their use as drugs, cosmetic prepns. and growth regulators comprising these derivs. as active compound and use of these derivs. for preparation of pharmaceutical compns., in biotechnol. processes, in cosmetics and in agriculture. Use of title compds. as mitotic or antimitotic compound, especially for treating cancer, psoriasis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft vs. host disease and gout, parasitoses such as those caused by fungi or protists, or Alzheimer's disease, or as anti-neurogenerative drugs, or to suppress

immunostimulation or for the treatment of proliferative skin diseases. Thus, 2-amino-6-(2-methoxybenzylamino)purine riboside was prepared as growth regulator, and antitumor agent.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:406956 CAPLUS
DN 141:235647
TI Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position
AU Ohno, Michihiro; Gao, Zhan-Guo; Van Rompaey, Philippe; Tchilibon, Susanna; Kim, Soo-Kyung; Harris, Brian A.; Gross, Ariel S.; Duong, Heng T.; Van Calenbergh, Serge; Jacobson, Kenneth A.
CS National Institute of Diabetes and Digestive and Kidney Diseases, DHHS, Laboratory of Bioorganic Chemistry, Molecular Recognition Section, National Institutes of Health (NIH), Bethesda, MD, 20892-0810, USA
SO Bioorganic & Medicinal Chemistry (2004), 12(11), 2995-3007
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 141:235647
AB We studied the structural determinants of binding affinity and efficacy of adenosine receptor (AR) agonists. Substituents at the 2-position of adenosine were combined with N6-substitutions known to enhance human A3AR affinity. Selectivity of binding of the analogs and their functional effects on cAMP production were studied using recombinant human A1, A2A, A2B, and A3ARs. Mainly sterically small substituents at the 2-position modulated both the affinity and intrinsic efficacy at all subtypes. The 2-cyano group decreased hA3AR affinity and efficacy in the cases of N6-(3-iodobenzyl) and N6-(trans-2-phenyl-1-cyclopropyl), for which a full A3AR agonist was converted into a selective antagonist; the 2-cyano-N6-Me analog was a full A3AR agonist. The combination of N6-benzyl and various 2-substitutions (chloro, trifluoromethyl, and cyano) resulted in reduced efficacy at the A1AR. The environment surrounding the 2-position within the putative A3AR binding site was explored using rhodopsin-based homol. modeling and ligand docking.
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.51	18.48
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

FILE 'REGISTRY' ENTERED AT 08:58:30 ON 28 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JUL 2008 HIGHEST RN 1036536-16-9
DICTIONARY FILE UPDATES: 27 JUL 2008 HIGHEST RN 1036536-16-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s l1 full
FULL SEARCH INITIATED 08:58:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     8425 TO ITERATE

100.0% PROCESSED     8425 ITERATIONS                          2343 ANSWERS
SEARCH TIME: 00.00.01

L4         2343 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     196.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -4.00

FILE 'CAPLUS' ENTERED AT 08:58:45 ON 28 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Jul 2008  VOL 149 ISS 5
FILE LAST UPDATED: 27 Jul 2008  (20080727/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l4
L5         233 L4

=> d bib abs hitstr 200-233 l5

L5   ANSWER 200 OF 233  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1979:68647  CAPLUS
DN   90:68647
OREF 90:10827a,10830a
TI   High performance liquid chromatographic analysis of cytokinins in Sorghum
     bicolor leaves
AU   Kannangara, T.; Durley, R. C.; Simpson, G. M.
CS   Crop Sci. Dep., Univ. Saskatchewan, Saskatoon, SK, Can.
SO   Physiologia Plantarum (1978), 44(3), 295-9
     CODEN: PHPLAI; ISSN: 0031-9317
DT   Journal
LA   English
AB   High-performance liquid chromatog. with octadecylsilica (Bondapak
     C18/Poracil B) column packing was used to purify and sep. cytokinins in
     sorghum leaf exts.  The column size was 56 + 0.21 cm.  By gradient
     elution with acidified water containing increasing amts. of MeOH, the major
     peaks of cytokinin activity, as determined by the callus tissue bioassay, were
     effectively separated from large amts. of extraneous impurities.  These
     cytokinins were separated further on a microoctadecylsilica column
     (μBondapak C18, 30 + 0.4 cm) with a gradient of acidified
     water-acetonitrile.  Zeatin and zeatin riboside gave distinct UV
     absorption peaks, which could be used for quant. estimation  Biol. activity
```

corresponded to the elution of these peak. These 2 cytokinins are the major cytokinins in sorghum leaves.
IT 50868-58-1
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in leaves of sorghum by high-performance liquid chromatog.)
RN 50868-58-1 CAPLUS
CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 201 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1978:420376 CAPLUS
DN 89:20376
OREF 89:3187a,3190a
TI Influence of different cytokinins on the transpiration and senescence of excised oat leaves
AU Biddington, N. L.; Thomas, T. H.
CS Natl. Veg. Res. Stn., Wellesbourne/Warwick, UK
SO Physiologia Plantarum (1978), 42(4), 369-74
CODEN: PHPLAI; ISSN: 0031-9317
DT Journal
LA English
AB To investigate the possibility that cytokinins control transpiration indirectly through affecting leaf senescence, a direct comparison was made of the effect of different cytokinins on transpiration and senescence of 4at leaves. Senescence was assessed by measuring chlorophyll loss. The synthetic cytokinins N6-benzyladenine (I) and kinetin delayed senescence and increased transpiration of oat leaves to a greater extent than did the naturally occurring compds. zeatin, N6-Δ2-isopentenyladenine (i6Ade) and 6-o-hydroxybenzyladenosine (II). During th early stages of the transpiration experiment zeatin showed similar or greater activity than I. This period was longest when freshly excised leaves were used, was reduced when leaves were used after incubation in distilled water in the dark for 20 h and was eliminated by incubation in cytokinin solution in the dark. After this period the activity of zeatin declined relative to I. The effect of cytokinins in increasing transpiration occurred only in the light; no effect was observed in the dark. I showed higher activity than zeatin in senescence tests but both cytokinins were less effective as the tests progressed, this decrease in activity being more rapid when older leaves were used. The results are discussed in relation to the mechanisms by which endogenous cytokinins might control senescence and transpiration in oat leaves and to the value of the oat leaf senescence and transpiration bioassays as tests for cytokinin activity of plant exts.
IT 50868-58-1
RL: BIOL (Biological study)
(senescence and transpiration in excised oat leaves response to)
RN 50868-58-1 CAPLUS
CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 202 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1978:51117 CAPLUS
DN 88:51117
OREF 88:8081a,8084a
TI Synthesis of N6- or 8-substituted 9-(β-D-arabinofuranosyl)adenines and their antiviral activities against herpes simplex and vaccinia viruses
AU Kaneko, Masakatsu; Kimura, Misako; Nishimura, Takuzo; Shimizu, Bunji
CS Cent. Res. Lab., Sankyo Co., Ltd., Tokyo, Japan
SO Chemical & Pharmaceutical Bulletin (1977), 25(10), 2482-9
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
AB 9-(β-D-Arabinofuranosyl)adenine (Ara-A) was prepared from AMP in 30% yield via 8,2'-O-cycloadenosine. 8-Substituted-amino Ara-A derivs. were obtained by aminolysis of 8,2'-O-cycloadenosine; N6-substituted Ara-A derivs. were obtained by treating 6-chloro-9-(β-D-arabinofuranosyl)purine with amines. In vitro antiviral activities of the N6- or 8-substituted Ara-A were determined by the degree of cytopathic effect inhibition.
IT 65397-90-2P 65397-91-3P 65397-92-4P
65397-93-5P 65397-94-6P 65397-95-7P
65397-96-8P 65397-97-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and virucidal activity of)
RN 65397-90-2 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(2-methylphenyl)methyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 65397-91-3 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(3-methylphenyl)methyl]-

(CA INDEX NAME)

Absolute stereochemistry.



RN 65397-92-4 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(4-methylphenyl)methyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 65397-93-5 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(2,3-
dimethylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 65397-94-6 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(2,4-dimethylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 65397-95-7 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(2,5-dimethylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 65397-96-8 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(2,6-dimethylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 65397-97-9 CAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-N-[(3,4-dimethylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 203 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1978:17157 CAPLUS
DN 88:17157
OREF 88:2715a,2718a
TI Antisenescent activity of natural cytokinins
AU Kuhnle, Judith A.; Fuller, Glenn; Corse, Joseph; Mackey, Bruce E.
CS WRRC, ARS, Berkeley, CA, USA
SO Physiologia Plantarum (1977), 41(1), 14-21
CODEN: PHPLAI; ISSN: 0031-9317
DT Journal
LA English
GI



I

AB The antisenescent activity of naturally occurring cytokinins (bases and ribosides) were evaluated by measuring chlorophyll retention in detached wheat (Triticum vulgare) leaf segments. 6-(3-Methyl-2-butenylamino)-2-

methylthiopurine (I) [20758-33-2] was the most active cytokinin followed by 6-(4-hydroxy-3-methyl-trans-2-butenylamino)purine (II) [1637-39-4]. Other D-ribofuranosylpurines tested were essentially inactive. 9-Ribosyl substitution did not affect the activity of II, (±)-6-(4-hydroxy-3-methylbutylamino)purine (III) [14894-18-9], or 6-(3-methyl-2-butenylamino)purine (IV) [2365-40-4], but lowered the activity of 6-(o-hydroxybenzylamino)purine [20366-83-0] and 6-(4-hydroxy-3-methyl-cis-2-butenylamino)purine [32771-64-5]. 2-Methylthio substitution increased the activity of III and IV and decreased or had no effect on the activity of other derivs. The activities of the simultaneously substituted 2-methylthio-9-ribosyl compds. are lower than those of their corresponding unsubstituted or 2-methylthio substituted bases with the exception of III. Structure-activity relations for chlorophyll retention did not parallel many of the relation found for callus tissue growth stimulation.

IT 50868-58-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antisenescent activity of)

RN 50868-58-1 CAPLUS

CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 204 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1977:536321 CAPLUS

DN 87:136321

OREF 87:21613a,21616a

TI Purine nucleotides

IN Imahori, Kazutomo; Suzuki, Koichi; Eguchi, Chikahiko

PA Ajinomoto Co., Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 52025795	A	19770225	JP 1975-102293	19750823
JP 60047280	B	19851021		
PRAI JP 1975-102293	A	19750823		

AB Aminophenylpurine nucleotides, ligands for carriers for affinity chromatog., were prepared by reducing the corresponding nitrophenylpurine nucleotides. Thus, 500mg Na N6-(p-nitrobenzyl)-5'-adenylate in MeOH-H2O was hydrogenated at atmospheric pressure using 5% Pd-C to give 387mg Na N6-(p-aminobenzyl)-5'-adenylate. Similarly prepared was Na salt of p-aminophenyl adenosine-5'-phosphate.

IT 63459-71-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrogenation of)

RN 63459-71-2 CAPLUS

CN 5'-Adenylic acid, N-[(4-nitrophenyl)methyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 63425-98-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 63425-98-9 CAPLUS
CN 5'-Adenylic acid, N-[(4-aminophenyl)methyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 205 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:449435 CAPLUS
DN 87:49435
OREF 87:7823a,7826a
TI Synthesis of AMP analogs and their use for studies on the allosteric site of rabbit muscle glycogen phosphorylase b
AU Eguchi, Chikahiko; Suzuki, Koichi; Imahori, Kazutomo
CS Fac. Med., Univ. Tokyo, Tokyo, Japan
SO Journal of Biochemistry (Tokyo, Japan) (1977), 81(5), 1401-11
CODEN: JOBIAO; ISSN: 0021-924X
DT Journal
LA English
AB In order to obtain a better understanding of the allosteric site of rabbit muscle phosphorylase b (I), 9 AMP analogs having a bulky hydrophobic benzene ring were synthesized and tested for activity as effectors. N6-Benzyl-AMP derivs. activated I to the same extent as AMP but were bound to I more tightly than AMP. N6-p-nitrobenzyl-AMP had the highest affinity for the AMP site. In an attempt to irreversibly modify the allosteric site of I, N6-p-bromoacetaminobenzyl-AMP (II) was synthesized. I was

maximally activated upon incorporation of 1.0 mol of II/I subunit, and its activity was .apprx.90% of that of native I measured in the presence of AMP. The modified I showed characteristics (e.g., kinetic parameters, stability, solubility, inhibition by glucose 6-phosphate, and state of aggregation) quite similar to those observed for native I in the presence of AMP. These results indicate that the AMP site of I was specifically labeled by II. The nature of the allosteric site of I is discussed based on the results obtained.

IT 40297-54-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40297-54-9 CAPLUS
CN Adenosine, N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 63074-11-3P 63554-91-6P 63554-92-7P
63591-33-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and phosphorylase b response to)
RN 63074-11-3 CAPLUS
CN 5'-Adenylic acid, N-[[4-[(bromoacetyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 63554-91-6 CAPLUS
CN 5'-Adenylic acid, N-[(4-aminophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 63554-92-7 CAPLUS
CN 5'-Adenylic acid, N-[[4-(acetylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 63591-33-3 CAPLUS
CN 5'-Adenylic acid, N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 206 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:449434 CAPLUS
DN 87:49434
OREF 87:7823a,7826a
TI Affinity labeling of adenine nucleotide-related enzymes with reactive adenine nucleotide analogs. II. Affinity labeling of phosphoglycerate kinase with a reactive AMP analog
AU Suzuki, Koichi; Eguchi, Chikahiko; Imahori, Kazutomo
CS Fac. Med., Univ. Tokyo, Tokyo, Japan
SO Journal of Biochemistry (Tokyo, Japan) (1977), 81(5), 1393-9
CODEN: JOBIAO; ISSN: 0021-924X
DT Journal
LA English
AB Affinity labeling of yeast and Bacillus stearothermophilus phosphoglycerate kinases (I) with a reactive AMP analog, N6-(p-bromoacetaminobenzyl)-AMP (II), was examined Complete loss of I activity was observed when 1 mol of II had reacted per mol of either I. Results on the effect of pH and substrate addition on the inactivation, titration of SH groups before and after modification, and kinetic studies with AMP analogs suggest that the modification occurs at 1 NH2 group at or near the substrate binding site. General affinity labeling of kinases is discussed.
IT 63074-11-3
RL: BIOL (Biological study)
(phosphoglycerate kinase affinity labeling with)
RN 63074-11-3 CAPLUS
CN 5'-Adenylic acid, N-[[4-[(bromoacetyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 207 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:401722 CAPLUS
DN 87:1722
OREF 87:307a,310a
TI Affinity labeling of adenine nucleotide-related enzymes with reactive adenine nucleotide analogs. I. Affinity labeling of glyceraldehyde 3-phosphate dehydrogenase and myokinase with a reactive AMP analog
AU Suzuki, Koichi; Eguchi, Chikahiko; Imahori, Kazutomo
CS Fac. Med., Univ. Tokyo, Tokyo, Japan
SO Journal of Biochemistry (Tokyo, Japan) (1977), 81(4), 1147-54
CODEN: JOBIAO; ISSN: 0021-924X
DT Journal
LA English
AB Rabbit muscle glyceraldehyde 3-phosphate dehydrogenase (GPD) and myokinase (MK) were rapidly inactivated by N6-(p-bromoacetaminobenzyl)-AMP under mild conditions. Complete inactivation was observed when 4 and 0.3 mol of the reagent with respect to enzyme were reacted with GPD and MK, resp. The inactivation of both enzymes was favored at higher pH and the enzymes were protected by addition of adenine nucleotide substrate. Modified GPD or MK had no affinity for AMP-Sepharose, in contrast to the native enzymes. Thus, the inactivation of GPD and MK by the reactive AMP analog can be regarded as an affinity labeling.
IT 63074-11-3
RL: BIOL (Biological study)
(glyceraldehyde phosphate dehydrogenase and myokinase affinity labeling by)
RN 63074-11-3 CAPLUS
CN 5'-Adenylic acid, N-[[4-[(bromoacetyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 208 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:121709 CAPLUS
DN 86:121709
OREF 86:19231a,19234a
TI Adenosine derivatives
IN Kampe, Wolfgang; Thiel, Max; Stach, Kurt; Schaumann, Wolfgang; Dietmann, Karl
PA Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 13 pp. Addn. to and Division of Ger. Offen. 1,670,175. CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2524284	A1	19761028	DE 1975-2524284	19750417
PRAI DE 1975-2524284	A	19750417		

GI



I

AB Vasodilating adenosines I (R = H; R1 = Cl, OH; R2 = 2-F3CC6H4CH2NH; R = H, R1 = OH, R2 = 2-Me-5-ClC6H3CH2NH) were prepared in 29-39% yields. Thus, I (R = Ac, R1 = R2 = Cl), 2-F3CC6H4CH2NH2, and Et3N in Me2CHOH were refluxed 2 h to give 39% I (R = H, R1 = Cl, R2 = 2-F3CC6H4CH2NH) (II), which gave 6% decrease in the exhaustion of O in arterial blood.
IT 62190-54-9P 62190-55-0P 62223-39-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and vasodilating activity of)
RN 62190-54-9 CAPLUS
CN Adenosine, 2-chloro-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 62190-55-0 CAPLUS
CN Adenosine, 1,2-dihydro-2-oxo-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 62223-39-6 CAPLUS
CN Adenosine, N-[(5-chloro-2-methylphenyl)methyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 209 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:572423 CAPLUS
DN 83:172423
OREF 83:27001a,27004a
TI Inhibitors of nucleoside transport. Structure-activity study using human erythrocytes
AU Paul, Brajeswar; Chen, Marianne F.; Paterson, Alan R. P.
CS McEachern Lab., Univ. Alberta, Edmonton, AB, Can.
SO Journal of Medicinal Chemistry (1975), 18(10), 968-73
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Of 68 nucleoside derivs. studied, the 9-β-D-ribofuranosylpurine [550-33-4] derivs. with S, O, or N atoms at the 6 position bearing alkyl or aralkyl groups most strongly inhibited transport of hypoxanthine [68-94-0] and guanosine [118-00-3] across the erythrocyte plasma membrane. 6-[(2-Hydroxy-5-nitrobenzyl)thio]-9-β-D-ribofuranosylpurine (I) [56964-73-9] and 2-amino-6-[(2-hydroxy-5-nitrobenzyl)thio]-9-β-D-ribofuranosylpurine (II) [41094-07-9] were very potent inhibitors, giving 50% inhibition of extracellular hypoxanthine and guanosine conversion to inosine in erythrocytes at concns. of 6.9 + 10-5 and 5.8 + 10-6mM, resp. The relation of structure and substituent hydrophobicity to activity is discussed.
IT 40297-54-9P 56964-69-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and nucleoside transport inhibition by)
RN 40297-54-9 CAPLUS
CN Adenosine, N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56964-69-3 CAPLUS
CN Adenosine, N-methyl-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 210 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:557754 CAPLUS
DN 83:157754
OREF 83:24691a,24694a
TI Synthesis and biological activities of some N6-(nitro- and -aminobenzyl)adenosines
AU Dutta, Shib P.; Tritsch, George L.; Cox, Clifford; Chheda, Girish B.
CS Gen. Clin. Res. Cent., Roswell Park Mem. Inst., Buffalo, NY, USA
SO Journal of Medicinal Chemistry (1975), 18(8), 780-3
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Of 12 title compds., prepared by direct alkylation of adenosine [58-61-7] by a benzyl bromide derivative to give the N1-derivative followed by rearrangement in base, or nucleophilic displacement of Cl in 6-chloropurine nucleosides with an amine, several were inhibitors of adenosine aminohydrolase [9026-93-1] and equal to or more active than N6-benzyladenosine [4294-16-0] as growth inhibitors of leukemia L1210 cells. The highest affinity for the substrate binding site of the enzyme was shown by N6-p-nitrobenzyladenosine (I) [40297-54-9] and N6-p-nitrobenzyl-2'-deoxyadenosine (II) [56527-33-4], which were also relatively nontoxic. 2-Amino-6-p-nitrobenzylamino-9-(β-D-ribofuranosyl)purine (III) [56527-38-9] and 2-amino-6-p-nitrobenzylaminopurine (IV) [56527-39-0] were better inhibitors of L1210 cells than N6-benzyladenosine.
IT 40297-54-9P 40896-40-0P 40896-43-3P
40958-96-1P 56527-34-5P 56527-35-6P
56527-36-7P 56527-38-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of)
RN 40297-54-9 CAPLUS
CN Adenosine, N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-40-0 CAPLUS
CN Adenosine, N-[(2-nitrophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-43-3 CAPLUS
CN Adenosine, N-[(2-methoxy-5-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40958-96-1 CAPLUS
CN Adenosine, N-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56527-34-5 CAPLUS
CN Adenosine, N-[(4-aminophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 56527-35-6 CAPLUS
CN Adenosine, N-[[4-(acetylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56527-36-7 CAPLUS
CN Adenosine, N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 56527-38-9 CAPLUS
CN Adenosine, 2-amino-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 211 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:510724 CAPLUS
DN 83:110724
OREF 83:17381a,17384a
TI Quantitative analysis of cytokinin using single-ion current monitoring
AU Thompson, A. G.; Horgan, R.; Heald, J. K.
CS Dep. Bot. Microbiol., Univ. Coll. Wales, Aberystwyth, UK
SO Planta (1975), 124(2), 207-10
CODEN: PLANAB; ISSN: 0032-0935
DT Journal
LA English
AB The levels of the cytokinin 6-(o-hydroxybenzylamino)-9-β-D-ribofuranosylpurine (o-OH BAP riboside) were measured in attached leaves of poplar (Populus robusta) using the technique of single-ion current monitoring (SICM) after extraction of the cytokinin. The use of 6-(p-hydroxybenzylamino)-9-β-D-ribofuranosylpurine (p-OH BAP riboside) as an internal standard enabled quant. measurements of recovery to be made.
IT 50868-58-1
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in poplar leaves, mass spectrometrics)
RN 50868-58-1 CAPLUS
CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 212 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:455693 CAPLUS
DN 83:55693
OREF 83:8779a,8782a
TI New cytokinin from Populus x robusta
AU Horgan, R.; Hewett, E. W.; Horgan, J. M.; Purse, J.; Wareing, P. F.
CS Dep. Bot. Microbiol., Univ. Coll. Wales, Abersywyth, UK
SO Phytochemistry (Elsevier) (1975), 14(4), 1005-8
CODEN: PYTCAS; ISSN: 0031-9422
DT Journal
LA English
AB A new cytokinin was isolated from mature leaves of poplar. Its structure was determined by uv and mass spectra and confirmed by synthesis as 6-(o-hydroxybenzylamino)-9-β-D-ribofuranosylpurine. This cytokinin has medium activity in the soybean callus test but shows high activity in the radish leaf senescence test.
IT 50868-58-1
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of Populus robusta)
RN 50868-58-1 CAPLUS
CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 213 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:400817 CAPLUS
DN 83:817
OREF 83:163a,166a
TI Effects of adenosine on metabolic and electrocardiographic parameters during a trial pacing in patients with coronary heart disease
AU Kugler, G.; Westermann, K. W.
CS II. Med. Klin. Poliklin., Univ. Hamburg-Eppendorf, Hamburg, Fed. Rep. Ger.
SO Zeitschrift fuer Kardiologie (1974), 63(11), 987-1000
CODEN: ZKRDAX; ISSN: 0300-5860
DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB The adenosine derivative, metrifudil (I) [23707-33-7], a specific coronary dilator, given i.v. to patients with coronary heart disease at 40 μg/kg increased coronary-venous O2 saturation following an increase in coronary blood flow but had a neg. effect during atrial pacing on electrocardiog.-registered hypoxic reaction and on the increase of lactate production Therapy of coronary heart disease with coronary dilators is questionable.
IT 23707-33-7
RL: BIOL (Biological study)
(heart disease treatment with)
RN 23707-33-7 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 214 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:140450 CAPLUS
DN 82:140450
OREF 82:22459a,22462a
TI 2-Chloroadenosines
IN Kikugawa, Kiyomi; Suehiro, Hideo; Ichino, Motonobu; Nakamura, Tokuro
PA Kohjin Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49110691	A	19741022	JP 1973-27982	19730312
	JP 55049595	B	19801212		
PRAI	JP 1973-27982	A	19730312		

GI For diagram(s), see printed CA Issue.
AB 2-Chloroadenosines I (Q = β-D-ribofuranosyl; R1 = R2 = H, alkyl, R1 = H, R2 = phenyl, benzyl, phenethyl with or without substituents) are prepared by treating 2-chloro-6-alkoxy-9-β-D-ribofuranosylpurines II (R = Me, Et, Pr) with NH3 or appropriate amines. Thus, 1 g II (R = Me) was heated with 100 ml saturated NH3 in MeOH at 100° for 4 hr in a sealed tube to give 100% I (R1 = R2 = H). Also prepared were I (R1 = H; R2 = PhCH2, iso-Bu, PhCH2CH2, Ph, 2,5-dimethylbenzyl).
IT 38583-88-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 38583-88-9 CAPLUS
CN Adenosine, 2-chloro-N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 215 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:146487 CAPLUS
DN 80:146487
OREF 80:23653a,23656a
TI N-Benzyladenosines
IN Kampe, Wolfgang; Fauland, Erich; Stach, Kurt; Stork, Harald; Schmidt, Helmut
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2244328	A1	19740321	DE 1972-2244328	19720909
	GB 1385830	A	19750305	GB 1973-41318	19730903
	ZA 7306044	A	19740925	ZA 1973-6044	19730904
	DK 130833	B	19750421	DK 1973-4859	19730904
	US 3880829	A	19750429	US 1973-393859	19730904
	DD 108086	A5	19740912	DD 1973-173293	19730905
	CH 579586	A5	19760915	CH 1973-12767	19730905
	CH 579588	A5	19760915	CH 1976-7353	19730905
	NL 7312260	A	19740312	NL 1973-12260	19730906
	CS 181727	B2	19780331	CS 1973-6219	19730906
	CS 181750	B2	19780331	CS 1976-6758	19730906
	FR 2198749	A1	19740405	FR 1973-32281	19730907
	AU 7360132	A	19740502	AU 1973-60132	19730907
	AT 7307784	A	19750715	AT 1973-7784	19730907
	AT 329192	B	19760426		
	ES 418572	A1	19760416	ES 1973-418572	19730907
	SU 515459	A3	19760525	SU 1973-1962240	19730907
	HU 168734	B	19760728	HU 1973-BO1461	19730907
	CA 1000273	A1	19761123	CA 1973-180715	19730907
	JP 49066695	A	19740627	JP 1973-102014	19730910
	JP 52029755	B	19770803		
	AT 7408451	A	19750915	AT 1974-8451	19741021
	AT 330370	B	19760625		
	US 3966916	A	19760629	US 1974-525795	19741121
	SU 533338	A3	19761025	SU 1975-2099424	19750120
	NL 7512407	A	19760227	NL 1975-12407	19751023
PRAI	DE 1972-2244328	A	19720909		
	US 1973-393859	A3	19730904		
	AT 1973-7784	A	19730907		

GI For diagram(s), see printed CA Issue.
AB Twenty-five benzyladenosiness I [R1 = cyclopentyl, cyclohexyl, or 2-buten-1-yl; R2 = H, 2-Me, 2,5-Me2, or 5,2-Cl(MeO); R3 = H or Ac], useful as antilipolytic, hypo-lipemic, and hypocholesterolemic agents, were prepared by amination of the chloro derivative II with the benzylamines optionally followed by acylation.
IT 52504-88-8P 52504-89-9P 52504-90-2P
52504-91-3P 52504-94-6P 52504-95-7P
52504-96-8P 52504-97-9P 52504-98-0P
52504-99-1P 52505-00-7P 52505-01-8P
52505-02-9P 52505-03-0P 52505-04-1P
52625-32-8P 52724-53-5P 52724-54-6P
52724-55-7P 52724-56-8P 52724-57-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52504-88-8 CAPLUS
CN Adenosine, N-cyclohexyl-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-89-9 CAPLUS
CN Adenosine, N-cyclopentyl-N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-90-2 CAPLUS
CN Adenosine, N-2-butenyl-N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 52504-91-3 CAPLUS
CN Adenosine, N-[(5-chloro-2-methoxyphenyl)methyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-94-6 CAPLUS
CN Adenosine, N-cyclohexyl-N-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-95-7 CAPLUS
CN Adenosine, N-cyclopentyl-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-96-8 CAPLUS
CN Adenosine, N-cycloheptyl-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-97-9 CAPLUS
CN Adenosine, N-[(2-methoxyphenyl)methyl]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-98-0 CAPLUS
CN Adenosine, N-cyclohexyl-N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52504-99-1 CAPLUS
CN Adenosine, N-cycloheptyl-N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52505-00-7 CAPLUS
CN Adenosine, N-[(5-chloro-2-methoxyphenyl)methyl]-N-cyclopentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52505-01-8 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52505-02-9 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52505-03-0 CAPLUS
CN Adenosine, N-cyclopentyl-N-[[5-methyl-2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52505-04-1 CAPLUS
CN Adenosine, N-cyclopentyl-N-[(2,5-dimethylphenyl)methyl]-, 2',3',5'-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52625-32-8 CAPLUS
CN Adenosine, N-cyclopentyl-N-[(2,5-dimethylphenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52724-53-5 CAPLUS
CN Adenosine, N-cyclohexyl-N-[(2-nitrophenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52724-54-6 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]-N-2-propenyl-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52724-55-7 CAPLUS
CN Adenosine, N-2-butenyl-N-[(2,5-dimethylphenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 52724-56-8 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]-N-(2-methyl-2-propenyl)-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52724-57-9 CAPLUS
CN Adenosine, N-[2-(acetyloxy)ethyl]-N-[(5-chloro-2-methoxyphenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 216 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:121282 CAPLUS
DN 80:121282
OREF 80:19535a,19538a
TI 2',3',5'-Tri-O-acyl-N6-benzyladenosines
IN Kampe, Wolfgang; Fauland, Erich; Thiel, Max; Roesch, Egon; Dietmann, Karl
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	DE 2238923	A1	19740214	DE 1972-2238923	19720808
	CA 1003411	A1	19770111	CA 1973-177826	19730731
	GB 1384518	A	19750219	GB 1973-36489	19730801
	ES 417471	A1	19760301	ES 1973-417471	19730801
	AU 7358857	A	19750206	AU 1973-58857	19730802
	CH 579587	A5	19760915	CH 1973-11307	19730803
	FR 2195434	A1	19740308	FR 1973-28648	19730806
	ZA 7305331	A	19740828	ZA 1973-5331	19730806
	NL 7310870	A	19740212	NL 1973-10870	19730807
	AT 7306918	A	19750115	AT 1973-6918	19730807
	AT 325784	B	19751110		
	JP 49045095	A	19740427	JP 1973-89161	19730808
PRAI	DE 1972-2238923	A	19720808		

GI For diagram(s), see printed CA Issue.

AB Eight acyladenosines I (R = Ac, Bz, or nicotinoyl, Rn1 = 2-Me, 2,5-Me2, 2,4,5-Me3, 2,5-MeOCl, or 2,5-MeSCl) were prepared in 45-85% yield by acylation of I (R = H) with Ac2O, BzCl, or nicotinoyl azide. The acyl derivs. had longer lasting effects on blood vessels and circulation than the starting compds. I (R = H).

IT 23707-33-7 34349-31-0 34349-36-5
34349-38-7 52622-05-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of)

RN 23707-33-7 CAPLUS

CN Adenosine, N-[(2-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-31-0 CAPLUS

CN Adenosine, N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-36-5 CAPLUS

CN Adenosine, N-[(5-chloro-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-38-7 CAPLUS
CN Adenosine, N-[[5-chloro-2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52622-05-6 CAPLUS
CN Adenosine, N-[(2,4,5-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50991-70-3P 50991-71-4P 52622-00-1P
52622-01-2P 52622-02-3P 52622-03-4P
52622-04-5P 52659-41-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50991-70-3 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]-, 2',3',5'-tri-3-pyridinecarboxylate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50991-71-4 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]-, 2',3',5'-tri-3-pyridinecarboxylate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52622-00-1 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52622-01-2 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52622-02-3 CAPLUS
CN Adenosine, N-[(5-chloro-2-methoxyphenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52622-03-4 CAPLUS
CN Adenosine, N-[[5-chloro-2-(methylthio)phenyl]methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52622-04-5 CAPLUS
CN Adenosine, N-[(2,4,5-trimethylphenyl)methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52659-41-3 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]-, 2',3',5'-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 217 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:93268 CAPLUS
DN 80:93268
OREF 80:14999a,15002a
TI Cytokinins in Populus x robusta. Light effects on endogenous levels
AU Hewett, E. W.; Wareing, P. F.
CS Dep. Bot. Microbiol., Univ. Coll. Wales, Aberystwyth, UK
SO Planta (1973), 114(2), 119-29
CODEN: PLANAB; ISSN: 0032-0935
DT Journal
LA English
AB Cytokinin levels in both attached and detached mature leaves of poplar (P. robusta) increased transiently after short periods of exposure to red light. The degree and rapidity of response seems dependent on the physiol. condition of the leaves. The cytokinin, 6-(2-hydroxybenzyl)aminopurine riboside, specifically increased after red light treatment. Diurnal changes of leaf cytokinins occurred, with a pronounced peak of activity being present at daybreak.
IT 50868-58-1
RL: BIOL (Biological study)
(of poplar, red light effect on)
RN 50868-58-1 CAPLUS
CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 218 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:27453 CAPLUS
DN 80:27453
OREF 80:4536h,4537a
TI 2',3',5'-Tri-O-nicotinoyl-N-(2-methylbenzyl)adenosines
IN Flohr, Hans; Fakhrai, Mohsen
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2218553	A1	19731108	DE 1972-2218553	19720417
	DE 2218553	B2	19770714		
PRAI	DE 1972-2218553	A	19720417		

GI For diagram(s), see printed CA Issue.
AB The adenosines I (R = H or Me), useful for the treatment of coronary and peripheral blood circulation insufficiency and as antihypertensives and antisclerotics, were prepared by successive reaction of adenosine with nicotinoyl chloride in pyridine and 5,2-RMeC6H3CH2NH2 in Me2CHOH-(Me2CH)2NH.
IT 50991-70-3P 50991-71-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50991-70-3 CAPLUS

CN Adenosine, N-[(2-methylphenyl)methyl]-, 2',3',5'-tri-3-pyridinecarboxylate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50991-71-4 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]-, 2',3',5'-tri-3-pyridinecarboxylate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 219 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1973:534312 CAPLUS
DN 79:134312
OREF 79:21771a,21774a
TI New cytokinin from Populus robusta
AU Horgan, R.; Hewett, E. W.; Purse, J. G.; Wareing, P. F.
CS Dep. Bot. Microbiol., Univ. Coll. Wales, Aberystwyth, UK
SO Tetrahedron Letters (1973), (30), 2827-8
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB A new cytokinin was isolated from the leaves of P. robusta and shown to be

6-[(o-hydroxybenzyl)amino]-9-β-D-ribofuranosylpurine (I).
IT 50868-58-1
RL: BIOL (Biological study)
(in Populus robusta)
RN 50868-58-1 CAPLUS
CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 220 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1973:413413 CAPLUS
DN 79:13413
OREF 79:2119a,2122a
TI Inhibitors of nucleoside and nucleotide metabolism
AU Henderson, J. F.; Paterson, A. R. P.; Caldwell, I. C.; Paul, B.; Chan, M. C.; Lau, K. F.
CS Cancer Res. Unit, Univ. Alberta, Edmonton, AB, Can.
SO Cancer Chemotherapy Reports, Part 2 (1973), 3(1), 71-85
CODEN: CCSUBJ; ISSN: 0069-0120
DT Journal
LA English
AB A total of 164 purine and pyrimidine derivs. and analogs were screened for inhibition of nucleoside and nucleotide metab in 4 test systems. Among a number of potent inhibitors identified, N6-(3-methyl-2-butenyl)-adenosine [7724-76-7] and 4-(dimethylamino)-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine (I) [20371-00-0] inhibited de novo purine biosynthesis in incubated Ehrlich ascites tumor cells, α-(-amino-9H-purin-9-yl)-α'-(hydroxymethyl)diglycolaldehyde-bis(phenylhydrazone) (II) [40297-52-7] inhibited adenine phosphoribosyltransferase [9027-80-9] from Ehrlich ascites tumor cells, 4-amino-5-iodo-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine [24386-93-4] inhibited adenine kinase [9027-72-9] activity in tumor cell exts., and 2-amino-6-[(p-fluorobenzyl)thio]-9-β-D-ribofuranosyl-9H-purine (III) [40297-53-8] and N6-(p-nitrobenzyl)-adenosine [40297-54-9] inhibited nucleoside transport (inosine synthesis) in incubated human erythrocytes.
IT 40297-54-9
RL: BIOL (Biological study)
(inosine formation by erythrocytes in response to)
RN 40297-54-9 CAPLUS
CN Adenosine, N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 221 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1973:124846 CAPLUS
DN 78:124846
OREF 78:20071a,20074a
TI N-Benzyladenosine derivatives
IN Kampe, Wolfgang; Fauland, Erich; Thiel, Max; Juhran, Wolfgang; Stork, Harald
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2136624	A	19730208	DE 1971-2136624	19710722
	GB 1340643	A	19731212	GB 1972-33537	19720618
	US 3845035	A	19741029	US 1972-271098	19720712
	ZA 7204891	A	19730530	ZA 1972-4891	19720717
	CH 569035	A5	19751114	CH 1975-10617	19720719
	CH 570420	A5	19751215	CH 1972-10795	19720719
	NL 7210023	A	19730124	NL 1972-10023	19720720
	ES 405022	A1	19750716	ES 1972-405022	19720720
	CA 979891	A1	19751216	CA 1972-147625	19720720
	SU 539532	A3	19761215	SU 1972-1812966	19720720
	FR 2146493	A1	19730302	FR 1972-26450	19720721
	AT 317446	B	19740826	AT 1972-6288	19720721
	AT 790673	A	19750415	AT 1973-7906	19720721
PRAI	DE 1971-2136624	A	19710722		

GI For diagram(s), see printed CA Issue.
AB Thirty-three title compds. (I; X = NHCH2C6H5-nRn; R: = Cl, OH NH2 or Br; Rn = e.g. 2-OH, 3,2-HOMe, 2,5 HOCl, 2,4- HOCl) were prepared by reaction of I (X = Cl) containing free or acetyl group-protected OH-groups with H2NCH2C6H5-nRn or from the adenosine derivative and ClCH2C6H5nRn. I had circulatory and antilipemic effects.
IT 40297-54-9P 40896-25-1P 40896-26-2P
40896-27-3P 40896-28-4P 40896-29-5P
40896-30-8P 40896-31-9P 40896-32-0P
40896-33-1P 40896-34-2P 40896-35-3P
40896-36-4P 40896-37-5P 40896-38-6P
40896-39-7P 40896-40-0P 40896-41-1P
40896-42-2P 40896-43-3P 40896-45-5P
40896-46-6P 40896-47-7P 40896-48-8P
40896-49-9P 40896-50-2P 40896-51-3P
40896-52-4P 40896-53-5P 40958-94-9P
40958-95-0P 40958-96-1P 40958-97-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40297-54-9 CAPLUS
CN Adenosine, N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-25-1 CAPLUS
CN Adenosine, N-[[2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-26-2 CAPLUS
CN Adenosine, N-[[3-(hydroxymethyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-27-3 CAPLUS

CN Adenosine, 2-chloro-N-[[2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-28-4 CAPLUS
CN 2H-Purin-2-one, 1,9-dihydro-6-[[[2-(hydroxymethyl)phenyl]methyl]amino]-9-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-29-5 CAPLUS
CN Adenosine, 2-bromo-N-[[3-(hydroxymethyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-30-8 CAPLUS
CN Adenosine, N-[[3-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-31-9 CAPLUS
CN Adenosine, N-[[4-chloro-2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-32-0 CAPLUS
CN Adenosine, N-[[5-(hydroxymethyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-33-1 CAPLUS
CN Adenosine, 2-amino-N-[[3-(hydroxymethyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-34-2 CAPLUS
CN Adenosine, 2-bromo-N-[[2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-35-3 CAPLUS
CN Adenosine, 2-chloro-N-[[3-(hydroxymethyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-36-4 CAPLUS
CN Adenosine, 2-chloro-N-[[4-chloro-2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-37-5 CAPLUS
CN Adenosine, 2-chloro-N-[[5-chloro-2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-38-6 CAPLUS
CN 2H-Purin-2-one, 1,9-dihydro-6-[[[3-(hydroxymethyl)-2-methylphenyl]methyl]amino]-9-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-39-7 CAPLUS
CN Adenosine, N-[[2-(hydroxymethyl)-5-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-40-0 CAPLUS
CN Adenosine, N-[(2-nitrophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-41-1 CAPLUS
CN Adenosine, N-[(5-methyl-2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-42-2 CAPLUS
CN Adenosine, 2-chloro-N-[(5-methyl-2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-43-3 CAPLUS
CN Adenosine, N-[(2-methoxy-5-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-45-5 CAPLUS
CN Adenosine, N-[(2-methyl-3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-46-6 CAPLUS
CN Adenosine, 2-chloro-N-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-47-7 CAPLUS
CN Adenosine, 2-chloro-N-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-48-8 CAPLUS

CN Adenosine, 2-chloro-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-49-9 CAPLUS
CN Adenosine, 2-chloro-N-[(2-methyl-3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-50-2 CAPLUS
CN Benzonitrile, 3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-51-3 CAPLUS
CN Benzonitrile, 4-[[(2-chloro-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-52-4 CAPLUS
CN Adenosine, N-[(4-cyanophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 40896-53-5 CAPLUS
CN Benzonitrile, 3-[[(2-chloro-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 40958-94-9 CAPLUS
CN Adenosine, N-[[5-chloro-2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40958-95-0 CAPLUS
CN Adenosine, 2-amino-N-[[2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40958-96-1 CAPLUS
CN Adenosine, N-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 40958-97-2 CAPLUS
CN Adenosine, N-[(3-cyano-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 222 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:502140 CAPLUS
DN 77:102140
OREF 77:16847a,16850a
TI N-[[(Hydrazinocarbonyl)phenyl]alkyl]adenosines
IN Jahn, Werner; Kampe, Wolfgang; Fauland, Erich; Juhran, Wolfgang; Stork, Harald
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2060189	A	19720615	DE 1970-2060189	19701208
	US 3787391	A	19740122	US 1971-201174	19711122
	NL 7116564	A	19720612	NL 1971-16564	19711202
	GB 1313459	A	19730411	GB 1971-56025	19711202
	SU 444368	A3	19740925	SU 1971-1721738	19711202
	ES 397613	A1	19750316	ES 1971-397613	19711202
	AU 7136492	A	19730607	AU 1971-36492	19711203
	CH 567045	A5	19750930	CH 1971-17640	19711203
	CH 568330	A5	19751031	CH 1975-8284	19711203
	CH 568331	A5	19751031	CH 1975-8285	19711203
	ZA 7108177	A	19720927	ZA 1971-8177	19711207
	HU 163227	B	19730728	HU 1971-BO1335	19711207
	AT 312172	B	19731227	AT 1971-10533	19711207

	AT 318821	B	19741125	AT 1972-9168	19711207
	AT 318822	B	19741125	AT 1972-9169	19711207
	CA 960656	A1	19750107	CA 1971-129590	19711207
	FR 2117935	A5	19720728	FR 1971-43996	19711208
	FR 2117935	B1	19750314		
	SU 515454	A3	19760525	SU 1973-1959114	19730824
	SU 576955	A3	19771015	SU 1973-1959113	19730824
PRAI	DE 1970-2060189	A	19701208		

GI For diagram(s), see printed CA Issue.

AB Fourteen title compds. (I, 2-, 3-, 4-, or 5-CONHNHR1; Q = CH2, CH2CH2, CH2CH2O; R = H, 2-Me, 3-Cl; R1 = H, p-ClC6H4CO, p-MeOC6H4CO, p-HOCH2CH2OC6H4CO, o-MeC6H4CO), useful as blood-circulation-active and serum-lipids-lowering agents, were prepared by reaction of tri-O-acetyladenosine with R(R1NHNHCO)C6H3QBr or of adenosine N-[R(EtO2C)C6H3Q] derivative with N2H4.H2O.

IT 38790-41-9P 38790-42-0P 38790-43-1P
38790-44-2P 38790-46-4P 38790-47-5P
38790-48-6P 38790-49-7P 38790-50-0P
38790-52-2P 38937-31-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38790-41-9 CAPLUS

CN Benzoic acid, 4-chloro-, 2-[4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-42-0 CAPLUS

CN Benzoic acid, 4-methoxy-, 2-[4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-43-1 CAPLUS
CN Benzoic acid, 4-(2-hydroxyethoxy)-, 2-[4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-44-2 CAPLUS
CN Benzoic acid, 2-methyl-, 2-[4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-46-4 CAPLUS
CN Benzoic acid, 4-methyl-3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-47-5 CAPLUS
CN Benzoic acid, 2-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-48-6 CAPLUS
CN Benzoic acid, 4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-49-7 CAPLUS
CN Benzoic acid, 2-methyl-3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-50-0 CAPLUS
CN Benzoic acid, 3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 38790-52-2 CAPLUS
CN Benzoic acid, 3-methyl-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38937-31-4 CAPLUS
CN Benzoic acid, 3-chloro-4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, 2-[4-(2-hydroxyethoxy)benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 223 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:502139 CAPLUS
DN 77:102139
OREF 77:16847a,16850a
TI N-(Acylbenzyl- and -phenethyl)adenosines
IN Kampe, Wolfgang; Fauland, Erich; Stork, Harald; Juhran, Wolfgang; Dietmann, Karl
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2059922	A	19720615	DE 1970-2059922	19701205
US 3817981	A	19740618	US 1971-199727	19711117
SU 469253	A3	19750430	SU 1971-1723201	19711130
SU 506294	A3	19760305	SU 1971-1913745	19711130
NL 7116563	A	19720607	NL 1971-16563	19711202
GB 1313290	A	19730411	GB 1971-56024	19711202
ES 397612	A1	19750316	ES 1971-397612	19711202
CH 567044	A5	19750930	CH 1971-17633	19711202
CH 573445	A5	19760315	CH 1975-8318	19711202
FR 2116517	A5	19720713	FR 1971-43419	19711203
FR 2116517	B1	19750801		
ZA 7108104	A	19720927	ZA 1971-8104	19711203
AU 7136493	A	19730607	AU 1971-36493	19711203
HU 163670	B	19731027	HU 1971-BO1334	19711203
AT 314094	B	19740325	AT 1971-10436	19711203
CA 960655	A1	19750107	CA 1971-129319	19711203
AT 323335	B	19750710	AT 1971-323335	19711203
PRAI DE 1970-2059922	A	19701205		

GI For diagram(s), see printed CA Issue.
AB Forty-five title compds. (I, Y = X,2-R(R1)C6H39CH2)nNH; n = 1,2; R = 3- or 4-carboxy, -alkoxycarbonyl, -carbamoyl, -allylcarbamoyl; R1 = H, Me; R2 = H, Cl, OH) (II), useful as hypolipemic agents with effects on circulation, were prepared by reaction of the corresponding I (Y = CL) (III) with X,2-R(R1)C6H3(CH2)nNH2 and subsequent saponification or amidation. Thus, refluxing III (R2 = H) and 3-EtO2C-C6H4CH2CH2NH2.HCl in EtOH in the presence of Et3N for 3 hr gave 65% II (n = 2, R = 3-EtO2C, R1 = R2 = H), which was heated in EtOH at 120° for 15 hr with NH3 to give 64% II (n = 2, R = 3-H2NCO, R1 = R2 = 5h).
IT 38823-49-3P 38823-50-6P 38823-51-7P
38823-52-8P 38823-53-9P 38823-54-0P
38823-55-1P 38823-56-2P 38823-59-5P
38823-60-8P 38823-62-0P 38823-64-2P
38823-65-3P 38823-66-4P 38823-67-5P

38823-68-6P 38823-69-7P 38823-72-2P
38823-73-3P 38823-74-4P 38823-76-6P
38823-77-7P 38823-78-8P 38823-79-9P
38823-81-3P 38823-82-4P 38823-84-6P
38823-85-7P 38823-86-8P 38823-88-0P
38823-89-1P 38823-90-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38823-49-3 CAPLUS
CN Benzoic acid, 3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-50-6 CAPLUS
CN Benzoic acid, 2-methyl-3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-51-7 CAPLUS
CN Benzoic acid, 4-[[(2-chloro-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-52-8 CAPLUS
CN Benzoic acid, 3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-53-9 CAPLUS
CN Benzoic acid, 2-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-54-0 CAPLUS
CN Benzoic acid, 4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-55-1 CAPLUS
CN Benzoic acid, 3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-56-2 CAPLUS
CN Benzoic acid, 4-methyl-3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-59-5 CAPLUS
CN Benzoic acid, 3-methyl-4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-60-8 CAPLUS
CN Benzoic acid, 3-[[(2-chloro-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-62-0 CAPLUS
CN Benzoic acid, 3-[[(2-bromo-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-64-2 CAPLUS
CN Benzoic acid, 3-[[(2-hydroxy-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-65-3 CAPLUS
CN Benzoic acid, 4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 38823-66-4 CAPLUS
CN Benzoic acid, 2-methyl-3-[[(9-β-D-ribofuranosyl-9H-purin-6-
yl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-67-5 CAPLUS
CN Benzoic acid, 2-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 38823-68-6 CAPLUS
CN Benzoic acid, 3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-69-7 CAPLUS
CN Benzoic acid, 4-methyl-3-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-72-2 CAPLUS
CN Benzoic acid, 3-methyl-4-[[(9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-73-3 CAPLUS
CN Benzoic acid, 3-[[(2-chloro-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-74-4 CAPLUS
CN Adenosine, N-[[3-(aminocarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-76-6 CAPLUS
CN Adenosine, N-[[2-(aminocarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-77-7 CAPLUS
CN Adenosine, N-[[4-(aminocarbonyl)phenyl]methyl]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-78-8 CAPLUS
CN Adenosine, N-[[4-(aminocarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-79-9 CAPLUS
CN Adenosine, N-[[5-(aminocarbonyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-81-3 CAPLUS
CN Adenosine, N-[[3-(aminocarbonyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-82-4 CAPLUS
CN Adenosine, N-[[4-(aminocarbonyl)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-84-6 CAPLUS
CN Adenosine, N-[[4-(aminocarbonyl)phenyl]methyl]-2-bromo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-85-7 CAPLUS
CN Adenosine, N-[[4-(aminocarbonyl)phenyl]methyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-86-8 CAPLUS
CN Adenosine, N-[[2-[(methylamino)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 38823-88-0 CAPLUS
CN Adenosine, N-[[3-[(methylamino)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-89-1 CAPLUS
CN Adenosine, N-[[4-[(methylamino)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38823-90-4 CAPLUS
CN Adenosine, N-[[2-methyl-3-[(methylamino)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 224 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:483708 CAPLUS
DN 77:83708
OREF 77:13769a,13772a
TI Clinical-pharmacological studies with a new orally active adenosine derivative
AU Schaumann, E.; Kutscha, W.
CS I. Med. Klin. Mannheim, Univ. Heidelberg, Mannheim, Fed. Rep. Ger.
SO Arzneimittel-Forschung (1972), 22(4), 783-90
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA German
AB Metrifudil [N6-(o-methylbenzyl)adenosine] (I) [23707-33-7] was tested in humans. Administration of 0.03 mg/kg i.v. and of 0.35 mg/kg orally increased the heart rate and cardiac output. Neither impairment of atrioventricular conduction nor other alterations of the electrocardiogram was observed Uneasiness and other side effects were caused by i.v. and oral administration of 0.1 and 0.47-0.53 mg I/kg, resp. The limit of tolerability was reached earlier if the speed of i.v. infusion exceeded 16 μg/kg/min. No critical changes in circulatory parameters were found. I.v. injection of I caused no inflammation or alteration of the veins. The concentration of serum fatty acids was lowered only by i.v. administration of I. A 50% absorption of I was estimated by comparing the increase of the heart rate after i.v. and oral administration.
IT 23707-33-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 23707-33-7 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

L5 ANSWER 225 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:475423 CAPLUS
DN 77:75423
OREF 77:12459a,12462a
TI N-(2,5-Dimethylbenzyl)-2-chloroadenosine
IN Kampe, Wolfgang; Fauland, Erich; Thiel, Max; Stork, Harald; Dietmann, Karl
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 5 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2055160	A	19720518	DE 1970-2055160	19701110
	NL 7115188	A	19720515	NL 1971-15188	19711104
	ZA 7107391	A	19720830	ZA 1971-7391	19711104
	GB 1315735	A	19730502	GB 1971-51344	19711104
	HU 164380	B	19740228	HU 1971-BO1330	19711104
	ES 396653	A1	19740601	ES 1971-396653	19711104
	SE 380026	B	19751027	SE 1971-14090	19711104
	CH 551424	A	19740715	CH 1971-16159	19711105
	CA 953715	A1	19740827	CA 1971-127184	19711108
	AT 303976	B	19721227	AT 1971-9668	19711109
	SU 413678	A3	19740130	SU 1971-1715932	19711109
	FR 2113889	A5	19720630	FR 1971-40243	19711110
	FR 2113889	B1	19750606		
PRAI	DE 1970-2055160	A	19701110		

GI For diagram(s), see printed CA Issue.
AB The title compound (I), useful in the treatment of atherosclerotic diseases, was prepared in 77.6% yield by refluxing the protected dichloro derivative (II) with 2,5-Me2C6H3CH2NH2 in the presence of Et3N and subsequent cleavage of the protecting Ac groups with NH3-saturated MeOH.
IT 38583-88-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 38583-88-9 CAPLUS
CN Adenosine, 2-chloro-N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 226 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:456780 CAPLUS
DN 77:56780
OREF 77:9361a,9364a
TI Antilipolytic and antihyperlipemic N-substituted adenosine derivatives
IN Stork, Harald; Schmidt, Felix Helmut; Thiel, Max; Fauland, Erich; Kampe, Wolfgang
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent

LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2052596	A	19720504	DE 1970-2052596	19701027
	US 3851056	A	19741126	US 1971-189409	19711014
	IL 37975	A	19750313	IL 1971-37975	19711020
	GB 1325970	A	19730808	GB 1971-48998	19711021
	ZA 7107083	A	19720830	ZA 1971-7083	19711022
	BE 774399	A1	19720425	BE 1971-109690	19711025
	AU 7134971	A	19730503	AU 1971-34971	19711025
	CA 983395	A1	19760210	CA 1971-126166	19711026
	FR 2111862	A5	19720609	FR 1971-38539	19711027
	FR 2111862	B1	19750801		
PRAI	DE 1970-2052596	A	19701027		

AB Forty-four title compds. [I; R = e.g. H or Cl; R1 = e.g. sec-Bu, EtCHMeCHMe, PrCHMe, o-MeC6H4CH2CH2, m-MeOC6H4CH2CHMe, o-MeC6H4CH(OH)CH2, PhOCH2CHMe, cyclopentyl, o-CF3C6H4, 2,5-Me2C6H3CH2, m-HO2CC6H4] decreased the concentration of free fatty acids in rat serum by 40-83% when given at 0.125-0.5 mg/kg. Thus, N6-sec-butyladenosine [35440-64-3] lowered serum free fatty acid concentration by 54% within 1 hr after i.p. administration of 0.5 mg/kg.

IT 38583-88-9
RL: BIOL (Biological study)
(for hyperlipemia treatment)

RN 38583-88-9 CAPLUS
CN Adenosine, 2-chloro-N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 227 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:154069 CAPLUS
DN 76:154069
OREF 76:25121a,25124a
TI Novel synthesis of N6-substituted adenosines and their coronary dilator activities
AU Shimizu, Bunji; Kaneko, Masakatsu; Saito, Akio; Nishino, Hiroshi; Mizuno, Hiroshi; Nakayama, Koichi; Ohshima, Takeshi; Koike, Hiroyuki
CS Sankyo Res. Lab., Tokyo, Japan
SO Sankyo Kenkyusho Nenpo (1971), 23, 117-23
CODEN: SKKNAJ; ISSN: 0080-6064
DT Journal
LA Japanese
AB N6-Substituted adenosine derivs. (PhCH2, PhCH2CH2, naphthylmethyl, Me2CHCH2, o-MeC6H4-CH2, m-MeC6H4CH2, p-MeC6H4CH2, furfurylmethyl) in addition to N6-benzyl-9-(β-D-arabinofuranosyl)adenine, and N6-benzyl-9-(β-D-glucopyranosyl)adenine were synthesized directly from adenosine by exchange amination reactions of the corresponding purine or pyrimidine bases. The mechanism of formation of these nucleosides and their coronary-dilating activities were described.
IT 23707-33-7P 35940-03-5P 35940-04-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as blood vessel dialators)

RN 23707-33-7 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 35940-03-5 CAPLUS
CN Adenosine, N-[(3-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 35940-04-6 CAPLUS
CN Adenosine, N-[(4-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 228 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1971:541121 CAPLUS
DN 75:141121
OREF 75:22273a,22276a
TI Coronary dilating N6-benzyladenosines
IN Kampe, Wolfgang; Fauland, Erich; Thiel, Max; Dietmann, Karl; Juhran, Wolfgang
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2007273	A	19710826	DE 1970-2007273	19700218
	SU 399134	A3	19730927	SU 1971-1616102	19710129
	US 3781273	A	19731225	US 1971-112424	19710203
	ES 388194	A1	19730501	ES 1971-388194	19710212
	NL 7102026	A	19710820	NL 1971-2026	19710216
	DK 123357	B	19720612	DK 1971-694	19710216
	HU 162739	B	19730428	HU 1971-BO1274	19710216
	CH 549596	A	19740531	CH 1971-2208	19710216
	CH 549600	A	19740531	CH 1974-2849	19710216
	CA 953714	A1	19740827	CA 1971-105563	19710216
	ZA 7101030	A	19711124	ZA 1971-1030	19710217
	FR 2081524	A5	19711203	FR 1971-5318	19710217
	FR 2081524	B1	19740927		
	AT 306251	B	19730410	AT 1971-1378	19710217
	AT 313483	B	19740225	AT 1972-1233	19710217
	JP 51016440	B	19760524	JP 1971-7691	19710218
	GB 1279946	A	19720628	GB 1971-1279946	19710419
PRAI	DE 1970-2007273	A	19700218		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I, where R = Me, MeS, or MeO, R1 = 5-Me, 5-Cl, 5-MeO, 5-iso-Pr, 5-F, 5-tert-Bu, 3-Me, or 3-Cl) were prepared wither by amination of the 6-chloro derivative or by N1-substitution of adenosine followed by alkaline rearrangement. Thus, 9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-6-chloropurine, 2,5-Me2C6H3CH2NH2, and Et3N in iso-PrOH was refluxed 3 hr and the protective Ac groups cleaved by NaOMe to give 61% I (R = Me, R1 = 5-Me). Similarly prepared were 11 other I.
IT 34349-31-0P 34349-32-1P 34349-33-2P
34349-34-3P 34349-35-4P 34349-36-5P
34349-37-6P 34349-38-7P 34349-39-8P
34349-40-1P 34349-41-2P 34422-72-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34349-31-0 CAPLUS
CN Adenosine, N-[(2,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-32-1 CAPLUS

CN Adenosine, N-[5-methyl-2-(methylthio)benzyl]- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-33-2 CAPLUS
CN Adenosine, N-(5-chloro-2-methylbenzyl)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-34-3 CAPLUS
CN Adenosine, N-(5-methoxy-2-methylbenzyl)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-35-4 CAPLUS
CN Adenosine, N-(2-methoxy-5-methylbenzyl)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-36-5 CAPLUS
CN Adenosine, N-[(5-chloro-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-37-6 CAPLUS
CN Adenosine, N-[(5-fluoro-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-38-7 CAPLUS
CN Adenosine, N-[[5-chloro-2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-39-8 CAPLUS
CN Adenosine, N-(5-tert-butyl-2-methylbenzyl)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-40-1 CAPLUS
CN Adenosine, N-[(2,3-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34349-41-2 CAPLUS
CN Adenosine, N-[(3-chloro-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34422-72-5 CAPLUS
CN Adenosine, N-(5-isopropyl-2-methylbenzyl)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 229 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1971:433660 CAPLUS
DN 75:33660
OREF 75:5316h,5317a
TI Pharmacological effects on coronary reactive hyperemia in conscious dogs
AU Juhran, W.; Voss, E. M.; Dietmann, K.; Schaumann, W.
CS Pharmakol. Lab., Boehring Mannheim G.m.b.H., Mannheim, Fed. Rep. Ger.
SO Naunyn-Schmiedebergs Archiv fuer Pharmakologie (1971), 269(1), 32-47
CODEN: NNAPBA; ISSN: 0340-5249
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB In conscious dogs, threshold doses of dipyridamole (I) and lidoflazine (II), which potentiate the dilation of coronary vessels by adenosine, increased reactive hyperemia in response to arterial occlusion lasting >30 sec, whereas threshold doses of coronary dilators, such as N6-(o-methylbenzyl)adenosine (III) and carbochromen (IV), which do not potentiate adenosine, did enhance reactive hyperemia for any duration of occlusion. Theophylline decreased the duration of reactive hyperemia, but not the excess flow. Procaine-HCl infused into the coronary artery caused a dose-dependent reduction of the reactive hyperemia. Apparently, appreciable amts. of adenosine were liberated only during complete anoxia for >30 sec. Under physiol. conditions coronary resistance was probably regulated by a nervous mechanism and not by adenosine liberation.
IT 23707-33-7
RL: BIOL (Biological study)
(hyperemia response to)

RN 23707-33-7 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 230 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1971:86054 CAPLUS
DN 74:86054
OREF 74:13963a,13966a
TI Inhibition of induced thrombocyte aggregation by adenosine and adenosine derivatives. II. Correlation between inhibition of the aggregation and peripheral vasodilatation
AU Dietmann, Karl; Birkenheier, H.; Schaumann, Wolfgang
CS Med. Forsch., Firma Boehringer Mannheim G.m.b.H., Mannheim-Waldhof, Fed. Rep. Ger.
SO Arzneimittel-Forschung (1970), 20(11), 1749-51
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB The ability of adenosine (I) and 20 adenosine derivs. to produce vasodilation in rabbits was correlated with their ability to antagonize ADP-induced thrombocyte aggregation in vitro. The N6-phenylalkyl substituted derivs., N6-(cis, trans-2-phenylcyclo-pentyl)adenosine and N6-(trans-dl-2-phenylcyclopentyl)adenosine (II), were more active than the aliphatic substituted derivs., 2-chloro-N6-propyl-, 2-chloro-N6-allyl-, and 2-chloro-N6-sec-butyladenosines, as well as the N6-benzyl derivs., 2-chloro-N6-benzyladenosine, 2-amino-N6-(2-chlorobenzyl)adenosine, N6-(o-xylyl)adenosine, N6-(o-trifluoromethylbenzyl)adenosine, and N6-(3,5-dimethoxybenzyl)adenosine. The most active derivative, II, was half as active as adenosine.
IT 23660-99-3 23661-01-0 23707-33-7
26783-35-7
RL: BIOL (Biological study)
(blood platelet aggregation and vasodilation by)
RN 23660-99-3 CAPLUS
CN Adenosine, N-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23661-01-0 CAPLUS
CN Adenosine, N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23707-33-7 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 26783-35-7 CAPLUS
CN Adenosine, 2-amino-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 231 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1970:21921 CAPLUS
DN 72:21921
OREF 72:4037a,4040a
TI 2-Aminoadenosine derivatives with cardiac activity
IN Koch, Klaus; Fauland, Erich; Stach, Kurt; Thiel, Max; Schaumann, Wolfgang; Dietmann, Karl
PA Boehringer, C. F., und Soehne G.m.b.H.
SO S. African, 25 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI ZA 6805477		19690128		
DE 1670265			DE	
FR 1587681			FR	
GB 1164580			GB	
US 3590029		19710629	US	19680822
PRAI DE		19670825		

GI For diagram(s), see printed CA Issue.
AB The title compds. [I, R = NHR1 (II), R1 = PhCH2, (Ph)MeCHC H2, Pr, o-ClC6H4CH2, iso-Bu, o-MeC6H4CH2, o-F3CC6H4, furf uryl, 3,4-(MeO)2C6H3CH2CH2, PhCH(OH)CHMe, PhCH(CO2H), allyl, cyclohexyl, 2-hydroxy-3-(m-cresoxy)propyl, 2-phenylcyclopropyl, 1-adamantyl, 2-(β-indolyl)ethyl, 2-indanyl, Bu, benzhydryl, 2,4-Cl2C6H3CH2, p-HOC6H4CH2CH2, o-PhOC6H4CH2, o-MeOC6H4CH2, PhCH2CH2, 3,5-(MeO)2C6H3CH2, p-ClC6H4CH2, 2-ethylhexyl, m-FC6H4CH2, HOCH2CH2, PhCHMe, 2-phenylcyclohexyl, PhOCH2CHMe, 2-hydroxy-3-(α-naphthoxy)propyl, Me2C:CHCH2, p-O2NC6H4-CHOHCH2, p-MeSO2NHC6H4CH2 or EtCHCH2OH] are prepared from I (R = Br) (III) and appropriate amines. II has cardiac and circulatory activities. For example, a mixture of 5 g III, 1.71 g PhCH2NH2 and 2.92 g Et3N in 50 ml Me2CHOH was refluxed 3 hr to give 29% II (R1 = PhCH2), m. 92° (decomposition). 2',3',5'-Tri-O-acetyl-2-amino-6-chloronebularin was also used in place of III, and the resulting substitution product was hydrolyzed to give II.
IT 26775-33-7P 26775-34-8P 26775-36-0P
26775-37-1P 26775-38-2P 26783-35-7P
26783-37-9P 26783-38-0P 26783-46-0P
26884-43-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26775-33-7 CAPLUS
CN 9H-Purine, 2-amino-6-[(o-phenoxybenzyl)amino]-9-β-D-ribofuranosyl- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26775-34-8 CAPLUS
CN Adenosine, 2-amino-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26775-36-0 CAPLUS
CN Adenosine, 2-amino-N-[(3,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26775-37-1 CAPLUS
CN Adenosine, 2-amino-N-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26775-38-2 CAPLUS
CN Adenosine, 2-amino-N-[(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26783-35-7 CAPLUS
CN Adenosine, 2-amino-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26783-37-9 CAPLUS
CN Adenosine, 2-amino-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26783-38-0 CAPLUS
CN Adenosine, 2-amino-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26783-46-0 CAPLUS
CN Methanesulfono-p-toluidide, α-[(2-amino-9-β-D-ribofuranosyl-9H-purin-6-yl)amino]- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26884-43-5 CAPLUS
CN Adenosine, 2-amino-N-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 232 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1969:115505 CAPLUS
DN 70:115505
OREF 70:21591a,21594a
TI N6-Aralkyl adenosine derivatives
IN Thiel, Max; Stach, Kurt; Jahn, Werner; Schaumann, Wolfgang; Dietmann, Karl
PA Boehringer, C. F., und Soehne G.m.b.H.
SO S. African, 15 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6707414		19680502		
	DE 1670171			DE	
	FR 1550512			FR	
	GB 1145789			GB	
	US 3506643		19700414	US	19671018
PRAI	DE		19661209		
	DE		19670711		

OS MARPAT 70:115505
GI For diagram(s), see printed CA Issue.
AB The title compds. (1), where halogen, alkyl, alkoxy, F3C or alkylthio, or two substituents may be H or a methylenedioxy, are prepared from the corresponding D-ribosides and benzylamines, or from the corresponding N'-substituted adenosine derivs. Thus, 8.2 g. tri-O-acetyl-6-chloro-9-β-D-ribosyl-9-H-purine and 7.2 g. 2-ClC6H4CH2NH2 in 120 cc. iso-PrOH were refluxed 2 hrs., worked up and the residue dissolved in 100 cc. MeOH, 10 cc. N NaOH solution added and the mixture refluxed 1 hr. to yield 4 g. I (R = 2-Cl), m. 182-3°. The following I were similarly prepared (R and m.p. given): 3,4-Cl2, 182-3°; 4-MeO, 146-7°; 3,4(MeO)2, 135-6°; 3,4,5-(MeO)3, 118-19°; 2,6-Cl2, 207-9°; 4-Cl, 174-5°; 3-Cl, 168-9°; 2-MeO, 147-8°; 2-Me, 157-8°; 3,5-(MeO)2, 191-2°; 2-MeS, 127-8°; 2-F3C, 160-1°; and 3-F3C, 111-12°. To a suspension of 10 g. 2',3'-O-isopropylideneadeno-sine in 200 cc. MeCN, 10 g. p-BrC6H4Br was added and the mixture refluxed 24 hrs. with stirring. The precipitate which formed was filtered off, dissolved in 150 cc. MeOH and an equal volume 2N NaOH solution was added. The mixture was heated on a steam bath 20 min., extracted with CHCl3, evaporated, and the residue dissolved in 200 cc. HCO2N. Water was added until the mixture became cloudy. The mixture was left standing 1 day at ambient temperature, after which it was evaporated in vacuo, and the residue made weakly alkaline with an aqueous solution of concentrated NH3 to yield 5.8 g. I (R = 4-Br), m. 168-9°. I exhibit an effect on blood vessels and circulation.
IT 23660-95-9P 23660-96-0P 23660-97-1P

23660-98-2P 23660-99-3P 23661-00-9P
23661-01-0P 23661-03-2P 23666-23-1P
23666-24-2P 23666-25-3P 23666-26-4P
23666-27-5P 23707-32-6P 23707-33-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23660-95-9 CAPLUS
CN Adenosine, N-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23660-96-0 CAPLUS
CN Adenosine, N-[(4-chlorophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23660-97-1 CAPLUS
CN Adenosine, N-[(3-chlorophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23660-98-2 CAPLUS
CN Adenosine, N-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23660-99-3 CAPLUS
CN Adenosine, N-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23661-00-9 CAPLUS
CN Adenosine, N-[o-(methylthio)benzyl]- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23661-01-0 CAPLUS
CN Adenosine, N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23661-03-2 CAPLUS
CN Adenosine, N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23666-23-1 CAPLUS
CN Adenosine, N-[(3,4-dichlorophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23666-24-2 CAPLUS
CN Adenosine, N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23666-25-3 CAPLUS
CN Adenosine, N-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23666-26-4 CAPLUS
CN Adenosine, N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23666-27-5 CAPLUS
CN Adenosine, N-[(4-bromophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23707-32-6 CAPLUS
CN Adenosine, N-[(2-chlorophenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 23707-33-7 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 233 OF 233 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1969:88212 CAPLUS
DN 70:88212
OREF 70:16513a
TI Adenosines
IN Kampe, Wolfgang; Thiel, Max; Stach, Kurt; Schaumann, Wolfgang; Dietmann, Karl
PA Boehringer, C. F., und Soehne G.m.b.H.
SO S. African, 35 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6707630		19680425		
	DE 1670175			DE	
	FR 1558462			FR	
	GB 1143150			GB	
PRAI	DE		19661221		

GI For diagram(s), see printed CA Issue.
AB A mixture of 4.5 g. tri-O-acetyl-2,6-dichloro-9-(β-D-ribofuranosyl)purine, 2.03 g. D-1-phenyl-2-aminopropane, and 2.02 g. Et3N was refluxed 2 hrs. in 50 ml. iso-PrOH, evaporated in vacuo, and taken up in Et2O-H2O, the ether phase washed twice with water, dried, and evaporated, the residue mixed with 40 ml. MeOH saturated with NH3, the mixture kept overnight at room temperature, treated with activated charcoal, and filtered, the filtrate evaporated, the residue dissolved in EtOAc, ligroine added dropwise with stirring, and the precipitate filtered off, washed with ligroine and dried to

give 47% 2-chloro-N-(D-1-phenyl-2-propyl)-adenosine, m. 65° (decomposition). Similarly prepared I (R1 = Cl) were (R, m.p., and % yield given): DL-PhCH2CHMe, 64-6° (chromatog. on silica gel with 6:1 CHCl3-MeOH), 66; p-ClC6H4CH2, 85-7°, 81; o-ClC6H4CH2, 80-3° (chromatog. on silica gel with 6:1 CHCl3-MeOH), 42; m-ClC6H4CH2, 65-7° (chromatog.) 23; PhCH2, 149-52° (benzene-EtOAc), 51; Ph-CH2CH2, 87-9° (decomposition) (chromatog.), 54; PhMeCH, 102-3° (decomposition) (chromatog.), 34; trans-2-phenylcyclopropyl, 118-20° (chromatog.), 36; Pr, 97-100° (decomposition) (chromatog.), 44; iso-Bu, 168-70° (EtOAc), 20; allyl, 123-6°, 68; iso-Pr, 92-5° (decomposition) (chromatog.), 64; L-threo-PhCH(OH)CHMe, 97-100° (MeOH), 34; L-erythro-PhCH(OH)CHMe, 130-2° (MeCN), 68; m-MeC6H4OCH2CH(OH)CH2, 84-6° (chromatog.), 45; 2-phenylcyclopentyl, 107-10° (chromatog.), 52; 2-phenylcyclohexyl, 108-11° (chromatog.), 30; o-MeOC6H4CH2, 106-9° (chromatog.), 43; 3,5-(MeO)2C6H3CH2, 187-9° (MeOH), 44; sec-Bu, 102-4° (chromatog.) 33; 2-hydroxypropyl 3-(α-naphthyloxy) 120-3°, (chromatog.), 34; L-(+)-threo-PhCH(OH)-CHCH2OH, 80-2° (chromatog.), 55; L-PhCH2CHMe, 94-6° (chromatog.), 62; o-MeC6H4CH2, 103-5° (chromatog.), 52; 2-phenoxycyclopropyl, 100-3° (chromatog.), 41; DL-m-MeOC6H4-CH(OH)CH2, 84-90° (chromatog.), 38; Me2CH(CH2)5, 103-5° (chromatog.), 34; DL-PhOCH2CHMe, 98-101° (chromatog.), 43; D-(+)-PhCH2CHCH2OH, 102-4° (chromatog.), 43; m-MeOC6H4CH2CH2, 86-9° (chromatog. on silica gel with 1:1 CHCl3-MeOH), 54; DL-[3,4-(MeO)2C6H4CH2CHMe], 104-6° (chromatog.), 21; DL-(m-MeC6H4OCH2CHMe), 102-5° (chromatog.), 35; L-PhOCH2CHMe, 108-10° (chromatog.), 36.5; m-HOC6H4CH2, 158-61° (MeCN), 25. Similarly prepared I (R1 = NH2) were (purine starting material, R, m.p., and % yield given); 2-amino-6-bromo-9-(β-D-ribofuranosyl)purine, o-Me-OC6H4CH2, -, -; 2-amino-6-bromonebularine, PhCH2, 92° (decomposition), 29. An ice-cooled solution of 18 g. NaNO2 in 140 ml. H2O was added with stirring over 20 min. to an ice cooled solution of 20 g. 2-amino-6-benzylthio-9-(β-D-ribofuranosyl)purine in 300 ml. HOAc, the mixture kept 1 hr. at 0° and overnight at room temperature and evaporated in vacuo, the residue washed 2-3 times with 50-100 ml. portions of water, evaporated in vacuo, the residue suction filtered, the solid washed with H2O, dissolved in MeOH, and repptd. with H2O to give 75% 6-benzythio-2-hydroxy-9-(β-D-ribofuranosyl)purine (II), m. 137-9°. A solution of 15 g. II in 200 ml. dioxane saturated with MeNH2 at 0° was heated in a glass autoclave 6 hrs. at 60° and evaporated in vacuo and the residue treated with activated charcoal to give 50% I (R = Me, R1 = OH), m. 185-90° (H2O). Similarly prepared was 33% I (R = allyl, R1 = OH), m. 220-2° (decomposition) (iso-PrOH). Other I (R1 = OH) were prepared from 3.9 g. II refluxed 2-5 hrs. with an amine in 50 ml. anhydrous dioxane or iso-PrOH (R, m.p., and % yield given): o-ClC6H4CH2, 170-2° (decomposition) (PrOH), 25; m-ClC6H4CH2, 152-5° (iso-PrOH), 39; p-ClC6H4CH2, 208-10° (decomposition), 78; p-MeOC6H4CH2, 166-8° (decomposition), 27; PhCH2, 160-2° (iso-PrOH), 37; PhCH2CH2, 159-61° (BuOH), 49; trans-2-phenylcyclopropyl, 153-6° (decomposition) (iso-PrOH), 27.5; Pr, 235-40°, 64; sec-Bu, 214-16° (decomposition) (iso-PrOH), 26°, L-PhCH2-CHMe, 148-50°, 38; D-PhCH2CHMe, 220-2° (iso-PrOH), 23; o-MeC6H4CH2, 180-2° (decomposition) (iso-PrOH), 33; PhOCH2CH(OH)CH2, 145-7° (iso-PrOH), 32; 2-hydroxy-3-(α-naphthyloxy)-propyl, 152-4° (iso-PrOH), 21; PhCH(OH)CH2, 217-19° (iso-PrOH), 37; m-MeC6H4OCH2CH(OH)CH2, 146-9° (iso-PrOH), 40. A solution of 5.3 g. NaNO2 in 10 ml. H2O was added with ice-cooling to a mixture of 5.0 g. I (R = o-MeOC6H4CH2, R1 = NH2) in 50 ml. glacial HOAc, the mixture kept overnight at room temperature and evaporated in vacuo, the residue taken up in CHCl3-H2O, and the CHCl3 phase dried and evaporated in vacuo to give I (R = o-MeOC6H4CH2, R1 = OH), m. 150-2° (PrOH). Similarly prepared was I (R = PhCH2, R1 = OH), m. 159-61° (iso-PrOH).

IT 23541-34-6P 23558-60-3P 23558-61-4P
23558-69-2P 23558-70-5P 23558-71-6P
23558-72-7P 23559-42-4P 23559-46-8P
23559-57-1P 23559-61-7P 23559-62-8P
23605-75-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23541-34-6 CAPLUS

CN Adenosine, 2-chloro-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23558-60-3 CAPLUS
CN Adenosine, 2-chloro-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23558-61-4 CAPLUS
CN Adenosine, 2-chloro-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23558-69-2 CAPLUS
CN Adenosine, N-[(2-chlorophenyl)methyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23558-70-5 CAPLUS
CN Adenosine, N-[(3-chlorophenyl)methyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23558-71-6 CAPLUS
CN Adenosine, N-[(4-chlorophenyl)methyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23558-72-7 CAPLUS
CN Adenosine, 1,2-dihydro-N-[(4-methoxyphenyl)methyl]-2-oxo- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 23559-42-4 CAPLUS
CN Adenosine, 2-chloro-N-[(3,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23559-46-8 CAPLUS
CN Adenosine, 2-chloro-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23559-57-1 CAPLUS
CN Adenosine, 1,2-dihydro-N-[(2-methylphenyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23559-61-7 CAPLUS
CN Adenosine, 2-chloro-N-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23559-62-8 CAPLUS
CN Adenosine, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23605-75-6 CAPLUS
CN Adenosine, 2-chloro-N-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.